Efficacy and safety study of apixaban, rivaroxaban, and warfarin in patients with venous thromboembolism
Latest Information Update: 10 Dec 2020
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2020 New trial record